Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment

Vanda Pharmaceuticals (NASDAQ:VNDA) shares are trading higher during the premarket session on Monday following the announcement of FDA approval for Bysanti (milsaperidone), a new treatment for bipolar I disorder and schizophrenia.FDA ApprovalThe FDA’s approval of Bysanti marks a significant milestone for Vanda, as it is positioned as a first-line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults.Bysanti is a new chemical entity (NCE ...